Hep C Discussion Forum

Members Login
Username 
 
Password 
    Remember Me  
Chatbox
Please log in to join the chat!
Post Info TOPIC: European Medicines Agency Validates Gileadís Marketing Application for Sofosbuvir


Guru

Status: Offline
Posts: 820
Date:
RE: European Medicines Agency Validates Gileadís Marketing Application for Sofosbuvir
Permalink  
 


Sounds good to me.



__________________

58 yo..Relapsed in 99 and again in 2004. Started triple therapy with Victrelis July 22,2012.† genotype 1a. week 8,12,16,24 VL Undetectable..E.O.T -- 6-22-2013,,,EOT + 24., UND.†

SVR !!!

~Bob~



Guru

Status: Offline
Posts: 895
Date:
RE: European Medicines Agency Validates GileadÔŅĹs Marketing Application for Sofosbuvir
Permalink  
 


I can't wait! :D



__________________

Genotype: 3b

VL.ÔŅĹover 15, 000 000

Failed TX 2014: Interferon/Riba.

Cured using Sof/Dak combination.

I can eat cake again! <3†



Guru

Status: Offline
Posts: 791
Date:
RE: European Medicines Agency Validates Gileadís Marketing Application for Sofosbuvir
Permalink  
 


:)




__________________

GT 3 dg. 08-2012 / FibroScan: 5 kPa F1 / FibroTest: F0-1 A1 / SoC TX: PegInt 120mcg+Riba 1000mg UND from w8 relapse EOT+4w
01-2016 Sof+Dac+Riba UND from w8, SVR24!




Guru

Status: Offline
Posts: 5627
Date:
Permalink  
 

European Medicines Agency Validates Gilead`s Marketing Application for Sofosbuvir for the Treatment of Hepatitis C

Once-Daily Sofosbuvir will Receive an Accelerated Assessment by EMA - Designation Granted to New Medicines of Major Public Health Interest.

May. 21, 2013-- Gilead Sciences, Inc. today announced that the company`s Marketing Authorisation Application (MAA) for sofosbuvir, a once-daily oral nucleotide analogue inhibitor for the treatment of chronic hepatitis C virus (HCV) infection, which was submitted to the European Medicines Agency (EMA) on April 17, 2013, has been fully validated and is now under assessment. The data submitted in this MAA support the use of sofosbuvir and ribavirin (RBV) as an all-oral therapy for patients with genotype 2 and 3 HCV infection, and for sofosbuvir in combination with RBV and pegylated interferon (peg-IFN) for treatment-naÔve patients with genotype 1, 4, 5 and 6 HCV infection.

http://hcvadvocate.blogspot.ca/2013/05/european-medicines-agency-validates.html



__________________

Jill†

(71 yo, lives in UK)

Was Gen 3a,†

24wks Peg Ifn/Riba, Sep 2010 - Mch 2011

UND @ Wk.4, UND @ EOT,†

SVR Nov 2011 --> Still UND @ EOT + 4 yrs.

Page 1 of 1  sorted by
 
Quick Reply

Please log in to post quick replies.

Legal Disclaimer:

THIS FORUM, IT'S OWNERS, ADMINISTRATORS, MODERATORS AND MEMBERS DO NOT AT ANY TIME GIVE MEDICAL ADVICE AND IN ALL CASES REFER ANYONE HERE TO SEEK APPROPRIATE MEDICAL ADVICE FROM THEIR DOCTOR.